长期治疗埃尔特伦博巴格治疗无塑性贫血后的缺铁性贫血:单一机构的经验
Ryusuke Yamamoto1, Nobuhiro Hiramoto2, Yuya Nagai1
1Department of Hematology, Kobe City Medical Center General Hospital, 2-1-1, Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
International journal of hematology
|February 12, 2025
概括
在无形性贫血患者中长期使用ELTROMBOPAG (EPAG) 可能会导致由于铁化而导致缺铁性贫血 (IDA). 在经过一年以上的EPAG治疗后,在患有复发性或耐药性贫血的患者中考虑使用E-IDA.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 埃尔特罗姆波帕格 (EPAG) 是一种血栓形成素受体激动剂,对无形成性贫血 (AA) 有效.
- EPAG可以化多价,包括铁,这引发了人们对长期使用的铁状况的担忧.
研究的目的:
- 在AA患者中调查eltrombopag诱导的缺铁性贫血 (E-IDA) 的发生率和特征.
主要方法:
- 对36名AA患者的回顾性评估,这些患者接受了EPAG治疗.
- 分析E-IDA发生率,发病,临床表现和对补充铁的反应.
主要成果:
- 17% (6/36) 的患者发生了无出血的E-IDA,平均发病时间为1142.5天.
- 较高的累积EPAG剂量与E-IDA相关 (P=0.04).
- E-IDA呈现为复发性或耐药性贫血,通过口服铁补充剂得到缓解.
结论:
- 在AA患者中,E-IDA是长期EPAG治疗的潜在并发症.
- 考虑E-IDA在患有AA和EPAG超过一年的患者中,呈现出复发性或耐药性贫血.
- 补充铁是有效的管理E-IDA.
相关概念视频
01:22Bone Marrow Sampling and Transplants
276
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
276
01:14Erythropoiesis
4.0K
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
4.0K
02:45Blood Transfusion and Agglutination
10.7K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.7K